-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai and Hong Kong November 2, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
, Ltd.
, a leading innovative biopharmaceutical company dedicated to the development and commercialization of the first of its kind and/or best-in-class hematology and oncology therapies ( Abbreviated as "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) today announced that the National Medical Products Administration (NMPA) has approved ATG-008 (onatasertib) in combination with ATG-010 (selinexor) for the treatment of relapsed/refractory An open phase Ib study on the dose exploration and safety of diffuse large B-cell lymphoma (rrDLBCL)
.
The trial is in China with Sun Yat-sen University Cancer Center as the lead research center, and it is planned to be carried out in 10 domestic research centers
.
The study is divided into a dose exploration phase and a dose expansion phase.
The enrolled subjects with relapsed/refractory diffuse large B-cell lymphoma will receive the combination therapy of ATG-008 and ATG-010
ATG-008 is a potent and selective inhibitor of mammalian target of rapamycin (mTOR) kinase, which simultaneously inhibits mTORC1 and mTORC2
.
ATG-008 inhibits cell growth and induces apoptosis in multiple hematoma cell lines, including 23 DLBCL cell lines
.
Professor Cai Qingqing, a professor at Sun Yat-sen University Affiliated Tumor Hospital, doctoral supervisor, and head of the Lymphoma Group of the Oncology Branch of the Guangdong Medical Association, said: “DLBCL is one of the most common types of non-Hodgkin’s lymphoma, about 30- 40% of patients will experience relapse or refractory
.
Patients with relapse and refractory have a poor prognosis and limited treatment options
.
Dr.
Mei Jianming, founder, chairman and CEO of Deqi Pharmaceuticals, said: “I am very pleased that the National Medical Products Administration has approved ATG-008 combined with ATG-010 in the treatment of rrDLBCL for the dose exploration and safety of the open phase Ib clinical study.
About the MATCH test
The trial is a dose-exploring, open phase Ib clinical study aimed at treating adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) with ATG-008 (onatasertib) combined with ATG-010 (selinexor) Perform dose exploration and safety assessment
.
About Deqi Pharmaceutical
Deqi Pharmaceutical Co.
, Ltd.
(abbreviated as "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) is a leading R&D-driven biopharmaceutical company dedicated to providing the most advanced therapies and treatments for patients in Asia Pacific and even the world Tumors and other life-threatening diseases
.
Since its official operation in 2017, Deqi Pharmaceuticals has established a rich product pipeline that extends from pre-clinical to clinical stages through cooperative introduction and independent research and development
.
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
.
Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear
.
Source: Deqi Pharmaceutical Co.
